CL2008002005A1 - Composicion faramceutica solida, estable para administracion oral, que comprende una sal de vinflunina hidrosoluble y al menos un diluyente definido y un lubricante; uso para tratar el cancer. - Google Patents
Composicion faramceutica solida, estable para administracion oral, que comprende una sal de vinflunina hidrosoluble y al menos un diluyente definido y un lubricante; uso para tratar el cancer.Info
- Publication number
- CL2008002005A1 CL2008002005A1 CL2008002005A CL2008002005A CL2008002005A1 CL 2008002005 A1 CL2008002005 A1 CL 2008002005A1 CL 2008002005 A CL2008002005 A CL 2008002005A CL 2008002005 A CL2008002005 A CL 2008002005A CL 2008002005 A1 CL2008002005 A1 CL 2008002005A1
- Authority
- CL
- Chile
- Prior art keywords
- lubricant
- pharmaceutical composition
- water
- oral administration
- solid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
COMPOSICION FARAMCEUTICA SOLIDA, ESTABLE PARA ADMINISTRACION ORAL, QUE COMPRENDE UNA SAL DE VINFLUNINA HIDROSOLUBLE Y AL MENOS UN DILUYENTE DEFINIDO Y UN LUBRICANTE; USO PARA TRATAR EL CANCER.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0756421A FR2918566B1 (fr) | 2007-07-11 | 2007-07-11 | Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine. |
US97033407P | 2007-09-06 | 2007-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008002005A1 true CL2008002005A1 (es) | 2009-06-26 |
Family
ID=38868376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008002005A CL2008002005A1 (es) | 2007-07-11 | 2011-11-10 | Composicion faramceutica solida, estable para administracion oral, que comprende una sal de vinflunina hidrosoluble y al menos un diluyente definido y un lubricante; uso para tratar el cancer. |
Country Status (21)
Country | Link |
---|---|
US (1) | US9173842B2 (es) |
EP (1) | EP2187886A1 (es) |
JP (1) | JP2010533139A (es) |
KR (1) | KR20100047230A (es) |
CN (1) | CN101730533B (es) |
AR (1) | AR067499A1 (es) |
AU (1) | AU2008274223A1 (es) |
BR (1) | BRPI0814216A2 (es) |
CA (1) | CA2695039A1 (es) |
CL (1) | CL2008002005A1 (es) |
CO (1) | CO6160316A2 (es) |
FR (1) | FR2918566B1 (es) |
MA (1) | MA32045B1 (es) |
NZ (1) | NZ583040A (es) |
PA (1) | PA8789101A1 (es) |
RU (1) | RU2462248C2 (es) |
SA (1) | SA08290417B1 (es) |
TN (1) | TN2010000013A1 (es) |
TW (1) | TW200914018A (es) |
WO (1) | WO2009007388A1 (es) |
ZA (1) | ZA201000335B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012135856A2 (en) * | 2011-04-01 | 2012-10-04 | Spectrum Pharmaceuticals, Inc. | Very low dose vinorelbine for treatment of cancer |
WO2013145750A1 (ja) * | 2012-03-29 | 2013-10-03 | 杏林製薬株式会社 | カプセル製剤 |
CN108289890B (zh) | 2015-12-02 | 2021-04-27 | 日本新药株式会社 | 含有2-{4-[n-(5,6-二苯基吡嗪-2-基)-n-异丙基氨基]丁氧基}-n-(甲磺酰基)乙酰胺的医药组合物 |
CN106994121B (zh) * | 2016-01-26 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 一种用于治疗癌症的药物组合物 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4558053A (en) | 1983-12-21 | 1985-12-10 | Eli Lilly And Company | Naphthalene-1,5-disulfonate salts of dimeric indole-dihydroindole alkaloids |
US5369094A (en) * | 1990-11-29 | 1994-11-29 | The Administrators Of The Tulane Educational Fund | Polypeptide bombesin antagonists |
FR2707988B1 (fr) * | 1993-07-21 | 1995-10-13 | Pf Medicament | Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant. |
FR2759293B1 (fr) * | 1997-02-11 | 1999-04-30 | Ethypharm Lab Prod Ethiques | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie |
FR2761990B1 (fr) * | 1997-04-10 | 1999-06-25 | Pf Medicament | Derives halogenes antimitotiques d'alcaloides de vinca |
GB9903547D0 (en) | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
AU2002213119A1 (en) | 2000-10-13 | 2002-04-22 | Bristol-Myers Squibb Company | Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and vinorelbine and method of using the same |
US6890558B2 (en) * | 2002-05-31 | 2005-05-10 | R.P. Scherer Technologies, Inc. | Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment |
EP1530459B1 (en) | 2002-05-31 | 2010-03-31 | R.P. Scherer Technologies, LLC | Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment |
US20070232533A1 (en) * | 2003-05-09 | 2007-10-04 | Kazuo Umezawa | Use of Vinca Alkaloids and Salts Thereof |
FR2863891B1 (fr) * | 2003-12-23 | 2006-03-24 | Pf Medicament | Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation |
CZ2004964A3 (cs) | 2004-09-14 | 2006-03-15 | Pliva-Lachema A. S. | Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo |
WO2006040779A2 (en) | 2004-10-11 | 2006-04-20 | Natco Pharma Limited | Controlled release gastric floating matrix formulation containing imatinib |
BRPI0519466B8 (pt) * | 2004-12-30 | 2021-05-25 | Pf Medicament | dispersão sólida estável de um derivado de alcalóide de vinca e processo para a fabricação do mesmo |
FR2880274B1 (fr) | 2004-12-30 | 2007-04-13 | Pierre Fabre Medicament Sa | Dispersion solide stable d'un derive d'alcaloides de vinca et son procede de fabrication |
FR2894966B1 (fr) * | 2005-12-20 | 2008-03-14 | Pierre Fabre Medicament Sa | Nouvelle forme cristalline de la vinflunine |
WO2009105937A1 (zh) | 2008-02-29 | 2009-09-03 | 江苏豪森药业股份有限公司 | 长春瑞滨软胶囊及其制备方法和其应用 |
-
2007
- 2007-07-11 FR FR0756421A patent/FR2918566B1/fr not_active Expired - Fee Related
-
2008
- 2008-07-08 TW TW097125680A patent/TW200914018A/zh unknown
- 2008-07-09 US US12/668,367 patent/US9173842B2/en not_active Expired - Fee Related
- 2008-07-09 RU RU2010103934/15A patent/RU2462248C2/ru not_active IP Right Cessation
- 2008-07-09 PA PA20088789101A patent/PA8789101A1/es unknown
- 2008-07-09 KR KR1020107001420A patent/KR20100047230A/ko not_active Application Discontinuation
- 2008-07-09 BR BRPI0814216A patent/BRPI0814216A2/pt not_active IP Right Cessation
- 2008-07-09 AU AU2008274223A patent/AU2008274223A1/en not_active Abandoned
- 2008-07-09 JP JP2010515500A patent/JP2010533139A/ja active Pending
- 2008-07-09 NZ NZ583040A patent/NZ583040A/en not_active IP Right Cessation
- 2008-07-09 SA SA08290417A patent/SA08290417B1/ar unknown
- 2008-07-09 CN CN2008800239960A patent/CN101730533B/zh not_active Expired - Fee Related
- 2008-07-09 WO PCT/EP2008/058893 patent/WO2009007388A1/en active Application Filing
- 2008-07-09 EP EP08786000A patent/EP2187886A1/en not_active Withdrawn
- 2008-07-09 CA CA2695039A patent/CA2695039A1/en not_active Abandoned
- 2008-07-10 AR ARP080102967A patent/AR067499A1/es not_active Application Discontinuation
-
2010
- 2010-01-08 TN TNP2010000013A patent/TN2010000013A1/fr unknown
- 2010-01-18 ZA ZA201000335A patent/ZA201000335B/xx unknown
- 2010-01-25 MA MA32552A patent/MA32045B1/fr unknown
- 2010-02-03 CO CO10011475A patent/CO6160316A2/es unknown
-
2011
- 2011-11-10 CL CL2008002005A patent/CL2008002005A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008274223A1 (en) | 2009-01-15 |
SA08290417B1 (ar) | 2013-01-22 |
RU2010103934A (ru) | 2011-08-20 |
RU2462248C2 (ru) | 2012-09-27 |
MA32045B1 (fr) | 2011-02-01 |
CA2695039A1 (en) | 2009-01-15 |
PA8789101A1 (es) | 2009-04-23 |
JP2010533139A (ja) | 2010-10-21 |
CN101730533B (zh) | 2013-05-29 |
US9173842B2 (en) | 2015-11-03 |
BRPI0814216A2 (pt) | 2015-10-27 |
FR2918566B1 (fr) | 2009-10-09 |
CN101730533A (zh) | 2010-06-09 |
WO2009007388A1 (en) | 2009-01-15 |
CO6160316A2 (es) | 2010-05-20 |
EP2187886A1 (en) | 2010-05-26 |
TW200914018A (en) | 2009-04-01 |
TN2010000013A1 (en) | 2011-09-26 |
US20100196468A1 (en) | 2010-08-05 |
FR2918566A1 (fr) | 2009-01-16 |
ZA201000335B (en) | 2010-10-27 |
KR20100047230A (ko) | 2010-05-07 |
NZ583040A (en) | 2012-03-30 |
AR067499A1 (es) | 2009-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
AR061348A1 (es) | Preparados estables de laquinimod | |
CL2008001656A1 (es) | Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene. | |
CL2008000418A1 (es) | Uso de un antagonista de la il-23 para el tratamiento de una infeccion fungica. | |
CL2008000510A1 (es) | Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero. | |
AR077629A1 (es) | Mimetico de smac | |
CL2013002417A1 (es) | Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
ECSP11011307A (es) | Comprimidos para terapia de combinacion | |
CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
CL2012000626A1 (es) | Composición farmacéutica oral de liberación sostenida, que comprende dentro de una forma de dosificación única, (i) una matriz hidrofílica, (ii) una cantidad terapéuticamente eficaz de un compuesto no opioide que contiene amina, (iii) una sal de un fármaco aine, y (iv) opcionalmente un surfactante aniónico. | |
BRPI0818193A2 (pt) | composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto | |
ECSP12011799A (es) | Compuestos de espiropiperidina y uso farmacéutico de los mismos | |
CL2011001254A1 (es) | Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente a cd38 y al menos melfalan; y su uso para el tratamiento contra el cancer. | |
CL2009000882A1 (es) | Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer. | |
CL2007001435A1 (es) | Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer. | |
CL2008002319A1 (es) | Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
CL2012002404A1 (es) | Compuestos derivados de urea, inhibidores de inmunoproteasomas; composición farmacéutica que comprende al compuesto; utiles en enfermedades inmunes, cancer, inflamacion, infecciones, enfermedad neurodegenerativa, entre otras. | |
CL2008003061A1 (es) | Compuestos tienopirimidina y pirazolopirimidina, inhibidores de quinasa mtor y quinasa pi3; composicion farmaceutica que comprende a dichos compuesto; y su uso para tratar aterosclerosis, artritis, cancer, entre otras enfermedades. | |
UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. | |
BRPI0906576A2 (pt) | Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer | |
CL2007003645A1 (es) | Compuestos parasiticidas derivados de aril-pirazoles sustituidos; compuestos intermediarios; composicion farmaceutica; y uso para tratar una infeccion parasitaria. | |
UY30304A1 (es) | Moduladores de mglur5 i |